Population-based estimates of age-specific cumulative risk of breast cancer for pathogenic variants in ATM

Breast Cancer Res. 2022 Apr 1;24(1):24. doi: 10.1186/s13058-022-01518-y.

Abstract

Background: Multigene panel tests for breast cancer predisposition routinely include ATM as it is now a well-established breast cancer predisposition gene.

Methods: We included ATM in a multigene panel test applied to the Australian Breast Cancer Family Registry (ABCFR), a population-based case-control-family study of breast cancer, with the purpose of estimating the prevalence and penetrance of heterozygous ATM pathogenic variants from the family data, using segregation analysis.

Results: The estimated breast cancer hazard ratio for carriers of pathogenic ATM variants in the ABCFR was 1.32 (95% confidence interval 0.45-3.87; P = 0.6). The estimated cumulative risk of breast cancer to age 80 years for heterozygous ATM pathogenic variant carriers was estimated to be 13% (95% CI 4.6-30).

Conclusions: Although ATM has been definitively identified as a breast cancer predisposition gene, further evidence, such as variant-specific penetrance estimates, are needed to inform risk management strategies for carriers of pathogenic variants to increase the clinical utility of population testing of this gene.

Keywords: ATM; Age-specific cumulative risk; Breast cancer predisposition; Genetic risk factors; Penetrance.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Aged, 80 and over
  • Ataxia Telangiectasia Mutated Proteins / genetics
  • Australia / epidemiology
  • Breast Neoplasms* / epidemiology
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / pathology
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Tumor Suppressor Proteins / genetics

Substances

  • Tumor Suppressor Proteins
  • ATM protein, human
  • Ataxia Telangiectasia Mutated Proteins